Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Appointed director CC transcript Acq. announced Director departure
|
Adhera Therapeutics, Inc. (ATRX)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/12/2023 |
8-K
| Quarterly results |
08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
06/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs:
|
"original issue discount SENIOR SECURED PROMISSORY NOTE THIS ORIGINAL ISSUE DISCOUNT SENIOR SECURED PROMISSORY NOTE is duly authorized and validly issued at an original issue discount by ADHERA THERAPEUTICS, INC., a Delaware corporation . FOR VALUE RECEIVED, the Company promises to pay to or its permitted assigns , the principal sum of $ on the date that is the earlier of 12 month anniversary of the Original Issue Date, or June 22, 2024, and the date of the Qualified Financing or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate and then outstanding principal amount of this Note in accordance with the provisions hereof. Provided that there is no Event of Default, the Maturity Date may be extended si...",
"COMMON STOCK PURCHASE WARRANT Warrant Shares: Initial Exercise Date: June 22, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, , or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to the close of business on the fifth year six month anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from Adhera Therapeutics, Inc., a Delaware corporation , up to 500,000 shares of Common Stock . The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant issued pursuant to a Securities Purchase Agreement entered into as of the Initial Exe...",
"Article I DEFINITIONS 1.1 Definitions. In addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section ‎1.1: “Acquiring Person” shall have the meaning ascribed to such term in Section ‎4.5. “Action” shall have the meaning ascribed to such term in Section ‎3.1. “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. “Board of Directors” means the board of directors of the Company. “Closing” means the closing of the purchase and sale of the Securities pursuant to Section ‎2.1. “Closin...",
"SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of _______________ , is among Adhera Therapeutics, Inc., a Delaware corporation , all of the subsidiaries of the Company and the holders of the Company’ s Original Issue Discount Senior Secured Promissory Notes signatory hereto, their endorsees, transferees and assigns . W I T N E S S E T H: WHEREAS, pursuant to the Purchase Agreement , the Secured Parties have severally agreed to extend the loans to the Company evidenced by the Notes; WHEREAS, pursuant to a certain Subsidiary Guaranty, dated as of the date hereof , the Guarantors have jointly and severally agreed to guarantee and act as surety for payment of such Notes; and" |
|
05/05/2023 |
8-K
| Quarterly results |
05/04/2023 |
8-K
| Quarterly results |
05/02/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs:
|
"original issue discount SENIOR SECURED PROMISSORY NOTE THIS ORIGINAL ISSUE DISCOUNT SENIOR SECURED PROMISSORY NOTE is duly authorized and validly issued at an original issue discount by ADHERA THERAPEUTICS, INC., a Delaware corporation . FOR VALUE RECEIVED, the Company promises to pay to [●] or its permitted assigns , the principal sum of $[●] on the date that is the earlier of 12 month anniversary of the Original Issue Date, or [●], and the date of the Qualified Financing or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate and then outstanding principal amount of this Note in accordance with the provisions hereof. Provided that there is no Event of Default, the Maturity Date may...",
"COMMON STOCK PURCHASE WARRANT Warrant Shares: [●] Initial Exercise Date: [●] THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [●], or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to the close of business on the fifth year six month anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from Adhera Therapeutics, Inc., a Delaware corporation , up to [●] shares of Common Stock . The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant issued pursuant to a Securities Purchase Agreement entered into as o...",
"Article I DEFINITIONS 1.1 Definitions . In addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1: “Acquiring Person” shall have the meaning ascribed to such term in Section 4.5. “Action” shall have the meaning ascribed to such term in Section 3.1. “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. “Board of Directors” means the board of directors of the Company. “Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.1. “Closing Date” means the T...",
"SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of _______________ , is among Adhera Therapeutics, Inc., a Delaware corporation , all of the subsidiaries of the Company and the holders of the Company’ s Original Issue Discount Senior Secured Promissory Notes signatory hereto, their endorsees, transferees and assigns . W I T N E S S E T H: WHEREAS, pursuant to the Purchase Agreement , the Secured Parties have severally agreed to extend the loans to the Company evidenced by the Notes; WHEREAS, pursuant to a certain Subsidiary Guaranty, dated as of the date hereof , the Guarantors have jointly and severally agreed to guarantee and act as surety for payment of such Notes; and" |
|
02/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs:
|
"original issue discount SENIOR SECURED PROMISSORY NOTE THIS ORIGINAL ISSUE DISCOUNT SENIOR SECURED PROMISSORY NOTE is duly authorized and validly issued at an original issue discount by ADHERA THERAPEUTICS, INC., a Delaware corporation . FOR VALUE RECEIVED, the Company promises to pay to [●] or its permitted assigns , the principal sum of $[●] on the date that is the earlier of 12 month anniversary of the Original Issue Date, or [●], and the date of the Qualified Financing or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate and then outstanding principal amount of this Note in accordance with the provisions hereof. Provided that there is no Event of Default, the Maturity Date may...",
"COMMON STOCK PURCHASE WARRANT Warrant Shares: [●] Initial Exercise Date: [●] THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [●], or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to the close of business on the fifth year six month anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from Adhera Therapeutics, Inc., a Delaware corporation , up to [●] shares of Common Stock . The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant issued pursuant to a Securities Purchase Agreement entered into as o...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of ______________, by and between Adhera Therapeutics, Inc., a Delaware corporation , and each lender party that executes the signature page hereto as a purchaser . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities Act, as defined, contained in Section 4 thereof and/or Rule 506 thereunder, the Company desires to issue and sell to the Purchasers, and the Purchasers, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other goo...",
"SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of _______________ , is among Adhera Therapeutics, Inc., a Delaware corporation , all of the subsidiaries of the Company and the holders of the Company’ s Original Issue Discount Senior Secured Promissory Notes signatory hereto, their endorsees, transferees and assigns . W I T N E S S E T H: WHEREAS, pursuant to the Purchase Agreement , the Secured Parties have severally agreed to extend the loans to the Company evidenced by the Notes; WHEREAS, pursuant to a certain Subsidiary Guaranty, dated as of the date hereof , the Guarantors have jointly and severally agreed to guarantee and act as surety for payment of such Notes; and" |
|
01/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs:
|
"original issue discount SENIOR SECURED PROMISSORY NOTE THIS ORIGINAL ISSUE DISCOUNT SENIOR SECURED PROMISSORY NOTE is duly authorized and validly issued at an original issue discount by ADHERA THERAPEUTICS, INC., a Delaware corporation . FOR VALUE RECEIVED, the Company promises to pay to [●] or its permitted assigns , the principal sum of $[●] on the date that is the earlier of 12 month anniversary of the Original Issue Date, or [●], and the date of the Qualified Financing or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate and then outstanding principal amount of this Note in accordance with the provisions hereof. Provided that there is no Event of Default, the Maturity Date may...",
"COMMON STOCK PURCHASE WARRANT Warrant Shares: [●] Initial Exercise Date: [●] THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [●], or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to the close of business on the fifth year six month anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from Adhera Therapeutics, Inc., a Delaware corporation , up to [●] shares of Common Stock . The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant issued pursuant to a Securities Purchase Agreement entered into as o...",
"Article I DEFINITIONS 1.1 Definitions. In addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section ‎1.1: “Acquiring Person” shall have the meaning ascribed to such term in Section ‎4.5. “Action” shall have the meaning ascribed to such term in Section ‎3.1. “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. “Board of Directors” means the board of directors of the Company. “Closing” means the closing of the purchase and sale of the Securities pursuant to Section ‎2.1. “Closin...",
"SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of _______________ , is among Adhera Therapeutics, Inc., a Delaware corporation , all of the subsidiaries of the Company and the holders of the Company’ s Original Issue Discount Senior Secured Promissory Notes signatory hereto, their endorsees, transferees and assigns . W I T N E S S E T H: WHEREAS, pursuant to the Purchase Agreement , the Secured Parties have severally agreed to extend the loans to the Company evidenced by the Notes; WHEREAS, pursuant to a certain Subsidiary Guaranty, dated as of the date hereof , the Guarantors have jointly and severally agreed to guarantee and act as surety for payment of such Notes; and" |
|
12/02/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
11/22/2022 |
8-K
| Quarterly results |
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/09/2022 |
8-K
| Quarterly results |
10/06/2022 |
8-K
| Quarterly results |
09/09/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/25/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
08/18/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/04/2022 |
8-K
| Quarterly results |
07/06/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
06/27/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
06/17/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
04/29/2022 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
04/28/2022 |
3
| RICE CHARLES L JR (Director) has filed a Form 3 on Adhera Therapeutics, Inc. |
04/21/2022 |
3
| Waerness Trond Kydd (Director) has filed a Form 3 on Adhera Therapeutics, Inc. |
04/15/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
04/01/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
11/29/2021 |
3
| Subhan Zahed (Director) has filed a Form 3 on Adhera Therapeutics, Inc. |
11/22/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
11/16/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
11/12/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER US $131,250.00",
"COMMON STOCK PURCHASE WARRANT ADHERA THERAPEUTICS, INC. Warrant Shares: 476,190 Initial Issue Date: October 7, 2021 Aggregate Exercise Amount: $45,238.05 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, BLUE LAKE PARTNERS, LLC, a Delaware limited liability company, or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to the close of business on the three year anniversary of the Initial Issue Date , to subscribe for and purchase from ADHERA THERAPEUTICS, INC., a Delaware corporation , up to 476,190 shares of common stock of the Company . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price,...",
"SECURITIES PURCHASE AGREEMENT" |
|
|
|
|